Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

(2008) D. M. Goldenberg et al.   BLOOD

Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity

(2008) B. Li et al.   CANCER RESEARCH

Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics

(2008) E. A. Rossi et al.   CANCER RESEARCH

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels

(2008) Michael Stanglmaier et al.   INTERNATIONAL JOURNAL OF CANCER

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

(2008) Bruce D. Cheson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel and Engineered Anti–B-Cell Monoclonal Antibodies for Non-Hodgkin’s Lymphoma

(2008) Peter Martin et al.   SEMINARS IN HEMATOLOGY